About Us
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|
|
|
CDXS - Codexis| Previous Close | $23.48 | Open | $23.48 |
| Volume | 103.7K | Market Cap | 988.28M |
| Yield | Last Dividend |
| Global Proteinase K Market Analysis Repo... | 03/01/21 |
| DUBLIN--(BUSINESS WIRE)--The "Proteinase K Market Share, Size, Trends, Industry Analysis Report, By Therapeutic Area; By Form, By Regions; Segment For... | |
| Phenylketonuria Treatment Market Analysi... | 02/26/21 |
| Global Phenylketonuria Treatment Market Analysis to 2027 is a specialized and in-depth study of the pharmaceutical industry with a special focus on th... | |
| Codexis Factors Likely to Have Influence... | 02/24/21 |
| Codexis announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by??? | |
| Codexis (CDXS) may be moving closer to p... | 01/21/21 |
| Biosciences company Codexis, Inc. (NASDAQ: CDXS) has emerged stronger from a rough patch, supported mainly by the resilience of its partners to the vi... | |
| Global Biocatalysis and Biocatalyst Supp... | 01/07/21 |
| DUBLIN--(BUSINESS WIRE)--The "Leadership Quadrant of Biocatalysis and Biocatalyst Suppliers - 2021" report has been added to ResearchAndMarkets.com's ... | |
| Why BlackRock Stock Will Continue to Roc... | 12/31/20 |
| Organic growth and strong cash inflows should keep the company atop the asset-management pyramid. Also, Wall Street views on Codexis, IMAX, Alibaba, a... | |
| Codexis Announces Pricing of Public Offe... | 12/02/20 |
| REDWOOD CITY, Calif., Dec. 02, 2020 (GLOBE NEWSWIRE) ??? Codexis, Inc. (Nasdaq:CDXS), a leading protein engineering company, today announced the prici... | |
| Reviewing Codexis (NASDAQ:CDXS) & New Or... | 10/24/20 |
| Codexis (NASDAQ:CDXS) and New Oriental Energy & Chemical (OTCMKTS:NOEC) are both medical companies, but which is the better stock? We will compare the... | |
| Codexis, Inc. (NASDAQ:CDXS) Director Ber... | 10/24/20 |
| Codexis, Inc. (NASDAQ:CDXS) Director Bernard J. Kelley sold 2,500 shares of the firm???s stock in a transaction on Wednesday, October 21st. The shares... | |
| Insider Selling: Codexis, Inc. (NASDAQ:C... | 10/23/20 |
| Codexis, Inc. (NASDAQ:CDXS) Director Bernard J. Kelley sold 2,500 shares of the business???s stock in a transaction on Wednesday, October 21st. The sh... | |
| Codexis, Inc. (NASDAQ:CDXS) Receives Con... | 10/23/20 |
| Shares of Codexis, Inc. (NASDAQ:CDXS) have received an average recommendation of ???Buy??? from the seven ratings firms that are presently covering th... | |
| Covid-19 Positive Impact on Specialty En... | 10/15/20 |
| The Report scope furnishes with vital statistics about the current Specialty Enzymes Market status and manufacturers. It analyses the in-depth busines... | |
| Codexis and Molecular Assemblies Partner... | 06/23/20 |
| Partnership targets accelerating the commercialization of enzymatic DNA synthesis: Codexis invests cash and protein engineering for equity stake in Mo... | |
| Codexis Announces the Election of New Di... | 06/16/20 |
| REDWOOD CITY, Calif., June 16, 2020 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading protein engineering company and developer of??? | |
| Earnings Preview: Codexis (CDXS) Q1 Earn... | 04/27/20 |
| Codexis (CDXS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with t... | |
| The Daily Biotech Pulse: Roche Obtains F... | 03/13/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs March 12.) ... | |
| Codexis (CDXS) Q4 Earnings and Revenues ... | 02/27/20 |
| Codexis (CDXS) delivered earnings and revenue surprises of -66.67% and -11.41%, respectively, for the quarter ended December 2019. Do the numbers hold... | |
| Codexis, Inc. (NASDAQ:CDXS) Expected to ... | 11/12/19 |
| Equities analysts forecast that Codexis, Inc. (NASDAQ:CDXS) will post $22.82 million in sales for the current fiscal quarter, Zacks Investment Researc... | |
| Codexis (CDXS) Upgraded to Buy: What Doe... | 11/06/19 |
| Codexis (CDXS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). | |
| Codexis (CDXS) Reports Q2 Loss, Lags Rev... | 08/06/19 |
| Codexis (CDXS) delivered earnings and revenue surprises of -100.00% and -17.30%, respectively, for the quarter ended June 2019. Do the numbers hold cl... | |
| Codexis (CDXS) Presents At UBS Global He... | 05/22/19 |
| No summary available. | |
| Retail On Display (Stocks To Watch Podca... | 05/19/19 |
| No summary available. | |
| Codexis Bags Novartis as Software Custom... | 05/09/19 |
| The small-cap biotech now has three of the top 10 pharmaceutical companies using its protein engineering platform technology. | |
| Codexis, Inc. (CDXS) CEO John Nicols on ... | 05/06/19 |
| Codexis, Inc. (NASDAQ:CDXS) Q1 2019 Earnings Conference Call May 06, 2019, 04:30 PM ET Company Participants Jody Cain - LHA John Nicols - President an... | |
| Codexis (CDXS) Reports Q1 Loss, Tops Rev... | 05/06/19 |
| Codexis (CDXS) delivered earnings and revenue surprises of 16.67% and 5.06%, respectively, for the quarter ended March 2019. Do the numbers hold clues... | |
| Codexis beats by $0.03, beats on revenue | 05/06/19 |
| No summary available. | |
| Week 19 Breakout Forecast: Short-Term Pi... | 05/06/19 |
| No summary available. | |
| Codexis (CDXS) Q4 Earnings Beat Estimate... | 03/14/19 |
| Codexis (CDXS) delivered earnings and revenue surprises of 400.00% and -3.34%, respectively, for the quarter ended March 2019. Do the numbers hold clu... | |
| Codexis, Inc. (CDXS) CEO John Nicols on ... | 02/26/19 |
| No summary available. | |
| Codexis, Inc. 2018 Q4 - Results - Earnin... | 02/26/19 |
| No summary available. | |
| Buy rating | 03/01/21 |
| Stifel initiates coverage with Buy rating and announces Price Target of $30.00 | |
| Buy rating | 02/26/21 |
| HC Wainwright & Co. maintains Buy rating and raises Price Target from $21.00 to $26.00 | |
| Date | 2021-02-25 (AMC) | Est. (EPS/Rev.) | ($0.12)/ 20.88M |
| Actual (EPS/Rev.) | $-0.06/ $21.03 M | EPS (TTM) | 0 |
| Total Revenue | $1.3B | Total Liabilities | $2.1B |
| Cost of Revenue | $2.5B | Total cash flow | $3.2 |
| Total Assets | $29.98B |
| % Insider | 12.52% | % Institutional | 76.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.
